Treating Retinopathy of Prematurity with Dexamethasone Eye Drops: A Difference-in-Differences Study in Sweden Using...

Area of Science:

• Ophthalmology
• Neonatology
• Pharmacology

Background:

• Retinopathy of prematurity (ROP) is a leading cause of severe visual impairment in preterm infants.
• Traditional treatments for ROP, such as laser ablation and anti-VEGF injections, can be invasive.
• Identifying effective, less invasive interventions for ROP is crucial.

Purpose of the Study:

• To evaluate the impact of dexamethasone eye drops on the progression of type 2 retinopathy of prematurity (ROP).
• To determine if dexamethasone eye drops reduce the requirement for traditional ROP treatments.

Main Methods:

• A register-based cohort study comparing ROP treatment frequencies before and after dexamethasone introduction.
• Inclusion of preterm infants born before 30 weeks' gestation across four Swedish sites.
• Utilized difference-in-differences analysis to compare treatment rates between intervention and control sites.

Main Results:

• At the intervention site, traditional ROP treatment incidence decreased significantly in infants with severe ROP (72% to 13%) and all screened infants (5.6% to 1.8%).
• Control sites showed no significant changes in treatment rates.
• Adjusted analyses indicated a markedly larger decline in traditional ROP treatments at the intervention site (interaction OR, 0.05; P < 0.001).

Conclusions:

• Introduction of dexamethasone eye drops was associated with a significant reduction in traditional ROP treatments for infants with severe ROP.
• Low-dose dexamethasone eye drops may offer a simple, cost-effective, and noninvasive approach to manage ROP.
• Further research is recommended to validate these findings.